CALL - SPRINTER OPEN END - NOVO-NORDISK B | Real-time Boerse Frankfurt Warrants 04:21:02 2024-06-03 am EDT | ||
| 19.81 EUR | +0.25% |
|
| 1 month | +3.62% | ||
| 3 months | +15.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 19.81 | +0.25% |
| 24-05-31 | 19.76 | +0.36% |
| 24-05-30 | 19.69 | +0.61% |
| 24-05-29 | 19.57 | -0.25% |
| 24-05-28 | 19.62 | +0.05% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 04:21 am EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VP1K7P |
| ISIN | DE000VP1K7P8 |
| Date issued | 2020-03-24 |
| Strike | 185.6 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.13 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.35 € |
|---|---|
| Lowest since issue | 0.12 € |
| Spread | 0.01 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
